What is the appropriate management for hyperkalemia and hyponatremia?

Management of Hyperkalemia and Hyponatremia

For acute hyperkalemia with ECG changes, immediately administer IV calcium (10 mL of 10% calcium gluconate or calcium chloride) to stabilize the cardiac membrane, followed by insulin with glucose and nebulized beta-agonists to shift potassium intracellularly, then initiate potassium elimination strategies; for hyponatremia, the approach depends critically on whether it is symptomatic/severe (requiring hospitalization with fluid restriction <1-1.5L/day, diuretic modification, and potentially hypertonic saline) versus asymptomatic (managed with sodium and fluid restriction plus medication adjustment). 1, 2

Hyperkalemia Management

Acute Hyperkalemia Treatment Algorithm

The management follows a three-pronged approach based on severity and ECG findings 1:

1. Cardiac Membrane Stabilization (Immediate - within 1-3 minutes)

• IV calcium gluconate 10%: 10 mL for patients with ECG changes
• Use calcium chloride 10 mL if patient is in cardiac arrest
• This does not lower potassium but prevents arrhythmias 1, 3

2. Intracellular Shift (30-60 minutes onset)

• IV insulin 10 units + 50 mL dextrose (or adjust dextrose based on initial glucose)
• Nebulized salbutamol 20 mg in 4 mL (beta-2 agonist)
• IV sodium bicarbonate - only if metabolic acidosis is present
• Note: These provide temporary benefit (1-4 hours) and rebound hyperkalemia can occur after 2 hours 4

3. Potassium Elimination

• Loop diuretics (IV or oral) in hypervolemic, non-oliguric patients 1
• Hemodialysis for oliguric patients or ESRD 1
• Potassium binders: Newer agents (patiromer, sodium zirconium cyclosilicate) are preferred over sodium polystyrene sulfonate, which has fallen out of favor due to adverse effects 5, 3

Chronic/Recurrent Hyperkalemia

Critical principle: Do NOT discontinue RAASi therapy - discontinuation is associated with higher mortality and major adverse cardiovascular events 1. Instead:

1. Identify and remove reversible factors 6:

   • Review medications causing hyperkalemia (NSAIDs, potassium-sparing diuretics, beta-blockers, trimethoprim-sulfamethoxazole) 4
   • Ensure effective diuretic therapy if volume overloaded 7
   • Correct metabolic acidosis if present 7

2. Dietary modification - Evidence for strict low-potassium diets is lacking; focus on reducing non-plant sources of potassium rather than eliminating all high-potassium foods 1, 7

3. Potassium binders for long-term management to enable continuation of RAASi therapy 6

4. Monitor potassium within 1 week after acute episode resolution 1

Severity Classification

• Mild: >5.0 to <5.5 mEq/L
• Moderate: 5.5 to 6.0 mEq/L
• Severe: >6.0 mEq/L 4

Important caveat: Life-threatening arrhythmias can occur at different thresholds in different patients. Focus on clinical impact and ECG changes rather than rigid thresholds 1.

Hyponatremia Management

Asymptomatic Mild Hyponatremia (Serum Na >120 mEq/L)

Outpatient management 2, 8:

• Fluid restriction: 1-1.5 L/day initially, adjusted based on sodium levels
• Sodium restriction based on severity
• Reduce or discontinue diuretics temporarily
• Adjust laxatives (lactulose) to avoid excessive stooling causing fluid loss
• Adequate solute intake (salt and protein)
• Resume diuretics once sodium stabilizes >125 mEq/L 2

Severe or Symptomatic Hyponatremia (Serum Na <120 mEq/L or symptomatic)

Requires hospitalization 2, 8. Symptoms include cognitive changes, dizziness, seizures, nausea, vomiting.

Immediate interventions:

1. Discontinue or adjust diuretics and laxatives
2. Fluid restriction to less than urine output
3. Correct hypokalemia, especially with encephalopathy
4. Evaluate for precipitants (infections, medications)
5. Assess renal and cardiac function

Additional measures for severe cases:

• IV albumin for volume assessment and renal perfusion 2
• Oral vasoconstrictors (midodrine) to improve renal perfusion 2
• 3% hypertonic saline as 100-150 mL IV bolus for life-threatening cases or pre-transplant correction 2, 8
  • Critical warning: Avoid rapid correction to prevent osmotic demyelination syndrome
  • Gradual correction is preferable over rapid normalization 8

Hypervolemic Hyponatremia (e.g., cirrhosis, heart failure)

• Evaluate for non-hepatic causes (thyroid, adrenal, cardiac, renal disease, infection) 2
• If hypotensive (SBP <90 mmHg), consider holding beta-blockers 2
• Vaptans (vasopressin receptor antagonists) can be considered for short-term use in severe cases, particularly pre-transplant, but have declined in use due to adverse events including hepatic injury 2, 8

Recurrent/Refractory Hyponatremia

Requires multidisciplinary approach including transplant hepatology and nephrology 2. Options include:

• IV vasoconstrictor therapy
• Hypertonic saline infusion
• Vaptans (short-term only)
• Renal replacement therapy for severe kidney injury 2

Key Monitoring Points

For hyperkalemia:

• Monitor ECG continuously during acute treatment
• Recheck potassium within 1 week after acute episode 1
• Watch for rebound hyperkalemia 2 hours after initial treatment 4

For hyponatremia:

• Frequent biochemical monitoring during correction 8
• Monitor for overcorrection to prevent osmotic demyelination
• Once stabilized on potassium binders, additional monitoring beyond routine comorbidity checks is not necessary 6